TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company will engage in a fireside chat scheduled for April 7, 2025, at 9:30 a.m. Eastern Time.
Interested parties can access the webcast through the 'Events and Presentations' section on TScan's website at ir.tscan.com. The replay will remain available for 90 days following the event.
TScan Therapeutics (Nasdaq: TCRX), una società biotech in fase clinica che sviluppa terapie con cellule T ingegnerizzate per il trattamento del cancro, ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale sulla Salute di Needham. L'azienda parteciperà a una chiacchierata informale programmata per 7 aprile 2025, alle 9:30 ora orientale.
Le parti interessate possono accedere al webcast tramite la sezione 'Eventi e Presentazioni' sul sito web di TScan all'indirizzo ir.tscan.com. La registrazione rimarrà disponibile per 90 giorni dopo l'evento.
TScan Therapeutics (Nasdaq: TCRX), una empresa biotecnológica en etapa clínica que desarrolla terapias con células T ingenierizadas para el tratamiento del cáncer, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Salud de Needham. La compañía participará en una charla informal programada para 7 de abril de 2025, a las 9:30 a.m. hora del Este.
Las partes interesadas pueden acceder a la transmisión a través de la sección 'Eventos y Presentaciones' en el sitio web de TScan en ir.tscan.com. La repetición estará disponible durante 90 días después del evento.
TScan Therapeutics (Nasdaq: TCRX), 암 치료를 위한 TCR 엔지니어링 T 세포 요법을 개발하는 임상 단계의 생명공학 회사가 제24회 니드햄 가상 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사는 2025년 4월 7일 오전 9시 30분 동부 표준시에 예정된 화상 대화에 참여할 예정입니다.
관심 있는 분들은 TScan 웹사이트의 '이벤트 및 발표' 섹션을 통해 웹캐스트에 접근할 수 있습니다. 이벤트 후 90일 동안 다시 볼 수 있습니다.
TScan Therapeutics (Nasdaq: TCRX), une entreprise biopharmaceutique en phase clinique développant des thérapies par cellules T ingénierées pour le traitement du cancer, a annoncé sa participation à la 24ème Conférence Virtuelle Annuelle de Santé de Needham. L'entreprise participera à une discussion informelle prévue pour le 7 avril 2025 à 9h30, heure de l'Est.
Les parties intéressées peuvent accéder au webinaire via la section 'Événements et Présentations' sur le site de TScan à l'adresse ir.tscan.com. La rediffusion sera disponible pendant 90 jours après l'événement.
TScan Therapeutics (Nasdaq: TCRX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das TCR-ingenierte T-Zelltherapien zur Krebsbehandlung entwickelt, hat seine Teilnahme an der 24. jährlichen Needham virtuellen Gesundheitskonferenz bekannt gegeben. Das Unternehmen wird an einem informellen Gespräch teilnehmen, das für 7. April 2025, um 9:30 Uhr Eastern Time angesetzt ist.
Interessierte können über den Bereich 'Veranstaltungen und Präsentationen' auf der Website von TScan unter ir.tscan.com auf den Webcast zugreifen. Die Wiederholung wird für 90 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 9:30 a.m. Eastern Time.
A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-T™ Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs.
Contacts
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com
FAQ
When is TScan Therapeutics (TCRX) presenting at the Needham Healthcare Conference 2025?
How can investors watch TScan Therapeutics' (TCRX) Needham Conference presentation?
How long will TScan Therapeutics' (TCRX) Needham Conference presentation be available for replay?
What type of therapies is TScan Therapeutics (TCRX) developing?
